Can a class II antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?

Journal of the American College of Cardiology

Volumn 29, Issue 3, 1997, Pages 688-692

  Murakawa, Yuji ^a   Yamashita, Takeshi ^a   Kanese, Yukihiro ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; NIFEKALANT; PYRIMIDINONE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVERSION; DEFIBRILLATION; DOG; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; ACTION POTENTIAL; ANIMAL; DRUG EFFECT; HEART; TREATMENT OUTCOME;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; ELECTRIC COUNTERSHOCK; HEART; PYRIMIDINONES; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 0030615023     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00559-1     Document Type: Article

References (26)

1. Naccarelli GV, Doughterty AH, Wolbrette D. Antiarrhythmic drug-implantable cardioverter defibrillator interactions, In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders, 1995:1426-33.
2. Echt DS, Black JN, Barbey JT, Coxe DR, Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation. Circulation 1989;79:1106-17.
3. Dorian P, Fain E, Davy JM, Winkle RA. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy. J Am Coll Cardiol 1986;8:327-32.
4. Fain ES, Dorian R, Davy JK, Kates RE, Winkle RA. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986; 73:1334-41.
5. Kerber PE, Pandian NG, Jensen SR, et al. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol 1986;7:397-405.
6. Frame LH, Sheldon JH. Effect of recainam on the energy required for ventricular defibrillation in dogs as assessed with implanted electrodes. J Am Coll Cardiol 1988;12:746-52.
7. Hernandez R, Mann DE, Breckinridge S, Williams GR, Reiter MJ. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol 1989;14:777-81.
8. Marinchak RA, Friehling TD, Kline RA, Stholer J, Kowey PR. Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. PACE 1988;11:7-12.
9. Murakawa Y, Inoue H, Kuo TT, et al. Prolongation of intraventricular conduction time associated with fatal impairment of defibrillation efficacy during treatment with class I antiarrhythmic agents. J Cardiovasc Pharmacol 1995;25:194-9.
10. Echt DS, Gremillion ST, Lee JT, et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol 1994;5:752-60.
11. Dorian P, Wang M, David I, Feindel C. Oral clofilium produces sustained lowering of defibrillation energy requirements in canine model. Circulation 1991;83:614-21.
12. Dorian P, Newman D, Harris L, Downar F. Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone. Can J Cardiol 1994;10:193-200.
13. Nakaya H, Tohse N, Takeda Y, Kanno N. Effect of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993;109:157-63.
14. Sato R, Koumi S, Hisatome I, et al. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1995;274:469-74.
15. Jones DL. The defibrillation threshold: a reliable method for rapid determination of defibrillation efficacy. In: Estes NMM III, Manolis AS, Wang PJ, editors. Implantable Cardioverter-Defibrillator: A Comprehensive Textbook. New York: Marcel Dekker, 1994:29-54.
16. Babbs CF. Effect of pentobarbital anesthesia on ventricular defibrillation threshold in dogs. Am Heart J 1978;95:331-7.
17. Szabo TS, Jones DL, Klein GJ. Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs. J Cardiovasc Pharmacol 1988;12:377-83.
18. Natale A, Jones DL, Kleinstiver PW, Kim YH, Wood, Klein GJ. Effects of flecainide on defibrillation threshold in pigs. J Cardiovasc Pharmacol 1993;21:573-7.
19. Epstein AE, Ellenbogen KA, Kirk KA, Kay GN, Dailey SM, Plumb VJ. Clinical characteristics and outcome of patients with high defibrillation thresholds: a multicenter study. Circulation 1992;86:1206-16.
20. Jung W, Manz M, Pizzuli L, Pfeiffer D, Luderitz B. Effect of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70: 1023-7.
21. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82:2235-42.
22. Bardy GH, Ivey TD, Johnson G, Stewart RB, Greene HL. Prospective evaluation of initially ineffective defibrillation pulses on subsequent defibrillation success during ventricular fibrillation in survivors of cardiac arrest. Am J Cardiol 1988;62:718-22.
23. Opthof T, Misier R, Coronel R, et al. Dispersion of refractoriness in canine ventricular myocardium: effects of sympathetic stimulation. Circ Res 1991; 68:1204-15.
24. Misier ARR, Opthof T, van Hemel NM, et al. Dispersion of "refractoriness" in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Circulation 1995;91:2566-72.
25. Rubertsson S, Grenvik A, Wiklund L. Blood flow and perfusion pressure during open-chest versus closed-chest cardiopulmonary resuscitation in pigs. Crit Care Med 1995;23:715-25.
26. Boczar ME, Howard MA, Rivers EP, et al. A technique revisited: hemodynamic comparison of closed and open chest cardiac massage during human cardiopulmonary resuscitation. Crit Care Med 1995;23:498-503.